Imricor Seeks FDA 510(k) Clearance for Advantage-MR MRI-Guided EP System

An announcement from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) is now available.

Imricor Medical Systems has submitted its Advantage-MR electrophysiology (EP) Recorder/Stimulator system to the U.S. Food and Drug Administration for market clearance under the 510(k) pathway, a key step toward entering the U.S. market. The MR-conditional system acquires, processes and records intracardiac and surface ECG signals during EP studies and ablations, interfaces with MRI platforms from Siemens and Philips (and in future GE) to track Imricor’s MRI-compatible catheters via NorthStar, and integrates a programmable cardiac stimulator. By effectively acting as the connectivity “glue” that links catheters, MRI scanners, ablation generators, ECG systems and NorthStar into a unified interventional cardiac MRI lab solution, the Advantage-MR platform strengthens Imricor’s position in MRI-guided electrophysiology and could materially enhance its competitive standing and adoption prospects once cleared.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

Imricor Medical Systems, Inc. is a medical technology company focused on making interventional procedures safer and more cost-effective by enabling them to be performed under real-time MRI guidance rather than traditional X-ray fluoroscopy. The company is a pioneer in MRI-compatible products for cardiac catheter ablation, offering capital equipment such as the NorthStar Mapping System and Advantage-MR EP Recorder/Stimulator, along with single-use ablation and diagnostic catheters, steerable sheaths, and related tools. Its products are approved in the European Union, Saudi Arabia and New Zealand, with regulatory processes underway for the United States and other markets, including Australia.

Average Trading Volume: 234,119

Technical Sentiment Signal: Buy

Current Market Cap: A$612.1M

For an in-depth examination of IMR stock, go to TipRanks’ Overview page.